How to Fight Insurance Denials for Growth Hormone Therapy

Growth hormone (GH) replacement therapy—whether daily somatropin injections or newer weekly formulations like Skytrofa, Sogroya, and Ngenla—is a cornerstone treatment for children and adults with documented growth hormone deficiency and a range of genetic and medical conditions that impair linear growth. Yet despite robust FDA approvals spanning decades and comprehensive clinical guidelines, insurers routinely deny GH prescriptions. Denials cluster around a few recurring themes: arbitrary peak GH cutoffs stricter than evidence supports, demands for redundant testing, blanket exclusions of FDA-approved indications like idiopathic short stature (ISS) as "cosmetic," mandatory step-therapy requiring months or years on cheaper daily formulations before allowing weekly products, and vague "not medically necessary" determinations. This guide walks you through the most common denial templates, the specific clinical citations insurers must respect, and concrete steps to build a successful appeal.

Why Insurers Deny Growth Hormone Therapy

1. Peak GH cutoff below guideline thresholds

Many plans require a peak stimulated GH below 3 or 5 ng/mL on two provocative tests, even though the Endocrine Society's 2016 and 2019 guidance accepts 10 ng/mL as the diagnostic cutoff for pediatric GHD and acknowledges that cutoffs vary by assay and BMI. Plans may also reject macimorelin (Macrilen) test results or refuse to count arginine-GHRH, glucagon, or clonidine as valid stimuli.

2. Labeling FDA-approved indications "cosmetic" or "experimental"

Idiopathic short stature (ISS) has been FDA-approved since Humatrope's label expansion in July 2003 for children with height standard deviation score (SDS) ≤ –2.25 and predicted adult height more than 2 SD below mid-parental height. Turner syndrome, SHOX deficiency, small for gestational age (SGA) without catch-up growth, Noonan syndrome, Prader-Willi syndrome, and chronic kidney disease (CKD) are all on-label. Yet insurers still code these as "quality of life" or exclude them outright in policy language.

3. Step-therapy mandates and forced brand switching

Plans increasingly require 6–12 months of "failure" on a daily somatropin product—even when the patient is already on one and adherence is a documented problem—before approving a once-weekly formulation. They may also force switches between brands (e.g., Genotropin to Omnitrope biosimilar, or Norditropin to Humatrope) mid-treatment based solely on formulary tier, ignoring device differences and established therapy.

4. Overly narrow definitions of "adult GHD"

For adult growth hormone deficiency, insurers may demand proof of childhood-onset disease, refuse to cover adult-onset GHD (post-surgery, radiation, or traumatic brain injury), or impose age cutoffs (e.g., denying treatment after age 65). They may also require re-testing at the transition from pediatric to adult care using stricter cutoffs (e.g., peak GH <3 ng/mL on insulin tolerance test).

5. Denying IGF-1 therapy (Increlex) or macimorelin diagnostic

Increlex (mecasermin) is FDA-approved for severe primary IGF-1 deficiency (Laron syndrome and similar conditions where the GH receptor is defective), yet some plans categorize it as "experimental." Macimorelin, the FDA-approved oral GH stimulation test (December 2017), is sometimes rejected in favor of older, more invasive protocols.

The Citations Insurers Must Respect

When you appeal, reference these by name and year. Medical directors and peer reviewers are obligated to follow published national guidelines and FDA determinations of safety and efficacy.

FDA Approvals and Label History

• Humatrope (somatropin): First FDA approval 1987; ISS indication approved July 2003 (height SDS ≤ –2.25 + predicted adult height >2 SD below mid-parental height).
• Omnitrope (somatropin-zzs): Approved May 30, 2006—the first US biosimilar/follow-on biologic growth hormone, referenced to Genotropin.
• Increlex (mecasermin): FDA approval August 30, 2005 for severe primary IGF-1 deficiency.
• Macrilen (macimorelin): Oral GH provocative test approved December 20, 2017 for diagnosis of adult GHD.
• Skytrofa (lonapegsomatropin-tcgd): Weekly GH approved August 25, 2021 for pediatric GHD ≥1 year, ≥11.5 kg; adult GHD label expansion 2024.
• Sogroya (somapacitan-beco): Weekly GH approved September 2020 for adult GHD; pediatric GHD (≥2.5 years) April 28, 2023.
• Ngenla (somatrogon-ghla): Weekly GH approved June 27, 2023 for pediatric GHD ≥3 years.

Clinical Practice Guidelines

• Endocrine Society Clinical Practice Guideline (2016, reaffirmed 2019): "Evaluation and Treatment of Adult Growth Hormone Deficiency." Recommends peak GH <10 ng/mL on provocative testing (assay-dependent), and supports insulin tolerance test (ITT), arginine plus GHRH, glucagon, and macimorelin as valid stimuli.
• Growth Hormone Research Society (GRS) Consensus (2000, updated 2007, 2016): Pediatric GHD diagnostic criteria—two stimulation tests with peak GH <10 ng/mL (or <7 ng/mL in higher-specificity protocols); acknowledges BMI-adjusted cutoffs and assay variability.
• Pediatric Endocrine Society (PES) / Drug and Therapeutics Committee: Supports use of weekly GH formulations when adherence is documented as suboptimal on daily regimens.
• Turner Syndrome Study Group / Clinical Practice Guidelines (Bondy et al., 2007, updated 2017): GH is standard of care for Turner syndrome to optimize adult height, independent of GH stimulation test results.

Pivotal Trials and Real-World Evidence

• ISS registration trials (Leschek et al., NEJM 2004; Wit et al., J Clin Endocrinol Metab 2012): Demonstrated mean adult height gain 3.7–5.0 cm in treated ISS patients.
• SKYTROFA Phase III (enliGHten trial, Brod et al., J Clin Endocrinol Metab 2020): Non-inferiority of once-weekly lonapegsomatropin to daily somatropin in pediatric GHD, with improved treatment satisfaction and adherence.
• Sogroya pediatric trial (Juul et al., J Clin Endocrinol Metab 2022): Efficacy and safety of once-weekly somapacitan in children ≥2.5 years.
• Ngenla pivotal studies (Thornton et al., J Clin Endocrinol Metab 2021): Weekly somatrogon non-inferior to daily GH in height velocity over 12 months.

How to Argue Against Each Denial Reason

1. "Peak GH must be below 3 or 5 ng/mL; your child's was 4.6 and 7.8 ng/mL—denied"

Why this happens: The plan is imposing a cutoff stricter than the Endocrine Society and GRS consensus.

Your counter-argument:

• Cite the guideline standard. The Endocrine Society 2016/2019 guideline uses 10 ng/mL as the diagnostic threshold for most provocative tests; some protocols use 7 ng/mL for higher specificity.
• Note assay variability. GH assays are not standardized; a peak of 4.6 ng/mL on a polyclonal immunoassay may be equivalent to <3 ng/mL on a different platform. The WHO international standard (IS 98/574) was adopted to harmonize results, but real-world cutoffs remain assay- and lab-dependent.
• Provide corroborative evidence. Low IGF-1 (age- and sex-adjusted SDS below –2), low IGFBP-3, poor height velocity (SDS below –2 over 6–12 months), delayed bone age ≥2 years, and pituitary MRI abnormalities (ectopic posterior pituitary, hypoplastic anterior lobe, thin stalk—the "triad") all support true GHD even when peak GH is in the "gray zone."
• Demand the plan's Medical Policy explicitly cite which clinical guideline justifies a 3 or 5 ng/mL cutoff. If none exists, the denial is arbitrary.

Concrete steps:

1. Request the insurer's Medical Policy Bulletin (MPB) on growth hormone.

2. Obtain a letter from your pediatric endocrinologist stating: "Per Endocrine Society 2016 guideline, peak stimulated GH <10 ng/mL on two tests meets diagnostic criteria for GHD. Patient's results of 4.6 and 7.8 ng/mL, combined with IGF-1 SDS –2.6, ectopic posterior pituitary, and severe short stature, confirm severe GHD."

3. Cite the specific guideline by name in your appeal letter.

4. Attach growth curves showing height velocity below the 1st percentile and crossing percentiles downward.

2. "Idiopathic short stature / Turner / SHOX / SGA is cosmetic, not medically necessary"

Why this happens: Insurers interpret GH for non-classic GHD indications as enhancing appearance rather than treating disease.

Your counter-argument:

• ISS: FDA-approved July 2003 (Humatrope label). Criteria: height SDS ≤ –2.25 and predicted adult height >2 SD below mid-parental height. Trials (Leschek NEJM 2004) showed ~4 cm adult height gain. Short stature in this range increases psychosocial morbidity and limits vocational options.
• Turner syndrome: GH is standard of care per Turner Syndrome Consensus (Bondy 2007/2017). Does not require GH deficiency testing. Mean untreated adult height is 143 cm (~4'8"); GH treatment adds 5–10 cm. Also mitigates cardiovascular and metabolic comorbidities.
• SHOX deficiency / Léri-Weill dyschondrosteosis: FDA-approved indication. SHOX haploinsufficiency causes disproportionate short stature and forearm deformity; GH improves growth velocity and final height.
• SGA without catch-up: FDA-approved. Children born small for gestational age who remain below –2 SDS by age 2–4 have documented risk of metabolic syndrome and reduced adult height. Early GH initiation (age 2–4) yields best results.

Concrete steps:

1. Quote the exact FDA indication from the package insert (e.g., Norditropin PI: "treatment of short stature associated with Turner syndrome").

2. State: "This is an FDA-approved, on-label use. The FDA determination of safety and efficacy supersedes the plan's characterization as 'cosmetic.'"

3. Provide karyotype (45,X or mosaic for Turner), SHOX deletion report, or birth records (SGA: birth weight and length SDS below –2).

4. Include a letter from your endocrinologist explaining the medical necessity: "Turner syndrome patients face 30% risk of bicuspid aortic valve, hypothyroidism, and glucose intolerance. GH improves not only height but metabolic and cardiovascular outcomes."

3. "You must fail 12 months of daily somatropin before we approve Skytrofa / Sogroya / Ngenla"

Why this happens: Step-therapy policies treat weekly GH as a convenience upgrade rather than a clinically distinct option.

Your counter-argument:

• Adherence is a medical outcome. Pediatric adherence to daily injections averages 50–70% over 12 months. Missed doses reduce efficacy (lower height velocity, lower IGF-1) and waste money. If your family has documented adherence problems—e.g., electronic device logs showing ≥6 missed doses/month, or if work/school schedules make daily evening injections impractical—weekly GH is a medical-necessity solution, not a preference.
• FDA approved these products without requiring prior daily-GH failure. Skytrofa, Sogroya, and Ngenla pivotal trials enrolled both GH-naive and GH-experienced patients; efficacy and safety were established independently.
• Quality of life and treatment satisfaction are recognized endpoints. The SKYTROFA trial (Brod 2020) used validated instruments (GHD-CIM, ITQ) showing significantly better satisfaction and quality of life with weekly vs. daily GH.

Concrete steps:

1. Gather evidence of poor adherence: device download reports (Genotropin Pen, easypod adherence tracker), pharmacy refill gaps, endocrinologist notes documenting missed doses.

2. Obtain a letter: "Patient has had suboptimal adherence to daily Genotropin (documented 20% missed doses over past 6 months). Switching to Skytrofa weekly is medically necessary to achieve therapeutic IGF-1 levels and expected height velocity."

3. Request an exception to step therapy under the plan's medical-necessity or formulary-exception process. Many states (e.g., California AB 2472, New York step-therapy override laws) allow expedited override when the required step is likely to be ineffective or has already been tried.

4. Cite the FDA approval dates and pivotal trial names (enliGHten for Skytrofa, Juul 2022 for Sogroya pediatric, Thornton 2021 for Ngenla).

4. "Adult GHD coverage requires childhood-onset disease" or "You are too old for GH"

Why this happens: Plans misread the evidence base (which is strongest for childhood-onset) or impose arbitrary age caps to contain cost.

Your counter-argument:

• Adult-onset GHD is well-established. Causes include pituitary adenoma resection, craniopharyngioma, radiation (including total-body irradiation for hematopoietic stem-cell transplant), traumatic brain injury, Sheehan syndrome (postpartum pituitary necrosis), and lymphocytic hypophysitis. The Endocrine Society 2016 guideline explicitly covers adult-onset GHD.
• Re-testing at transition is guideline-concordant but the cutoff must be fair. The Endocrine Society recommends re-confirming GHD in young adults with childhood-onset disease (ages 18–25) using an ITT or equivalent; however, the cutoff remains ≤5–6 ng/mL (not <3).
• No upper age limit in guidelines. Studies in adults >60 show GH replacement improves body composition, bone density, and quality of life; there is no clinical rationale to deny coverage at age 65 or 70.

Concrete steps:

1. Document the etiology: operative note from pituitary surgery, radiation oncology summary (cranial dose in Gy and year), MRI showing empty sella.

2. Provide re-testing results: "Insulin tolerance test (ITT) performed June 2025: peak GH 2.8 ng/mL (cutoff ≤5 per Endocrine Society 2016). IGF-1 68 ng/mL, age-adjusted SDS –2.9."

3. Cite the guideline: "Endocrine Society Clinical Practice Guideline (2016) recommends GH replacement for adults with confirmed GHD, regardless of age, when peak GH is ≤5–6 ng/mL on ITT or equivalent."

4. If the plan cites a Medicare LCD (Local Coverage Determination) as precedent, note that Medicare LCDs are not binding on commercial plans and often lag behind national guidelines.

5. "Increlex is experimental" or "Macimorelin is not a valid test"

Why this happens: Lack of familiarity with niche FDA approvals.

Your counter-argument:

• Increlex (mecasermin): FDA-approved August 30, 2005 for severe primary IGF-1 deficiency (IGF-1 SDS below –3 despite normal or elevated GH). This includes Laron syndrome (GH receptor mutations), IGF-1 gene defects, and post-receptor signaling defects. It is not for GH-responsive GHD. Quote the FDA indication verbatim.
• Macimorelin (Macrilen): FDA-approved December 20, 2017 as an oral alternative to ITT for diagnosing adult GHD. Cutoff: peak GH ≤2.8 ng/mL (for BMI <30) or ≤1.1 ng/mL (BMI ≥30) at 30–90 minutes post-dose. Sensitivity and specificity are comparable to ITT. The FDA approval package and label are public.

Concrete steps:

1. Attach the FDA approval letter or package insert.

2. State: "Increlex is the only FDA-approved treatment for severe primary IGF-1 deficiency. There is no alternative."

3. For macimorelin, cite the approval date and provide test results: "Macimorelin test performed Jan 2026: peak GH 1.8 ng/mL at 45 min (BMI 27). Cutoff ≤2.8. Confirms adult GHD per FDA-approved protocol."

4. If the plan calls it "investigational," request the specific peer-reviewed evidence they relied upon; FDA approval by definition establishes a drug as non-investigational.

What We Do

We help patients and families compile the clinical records, lab reports, growth charts, genetic test results, MRI findings, and pharmacy logs that turn a vague "medically necessary" claim into a thoroughly documented, citation-backed appeal. We draft letters that speak the language medical directors understand—guideline names, FDA approval dates, trial acronyms—and we coordinate with your endocrinologist to ensure every piece of the puzzle is in the file before the peer-to-peer review or external appeal hearing. Our goal is to move your case from "pending" to "approved" as quickly as the evidence allows.

Sources

1. FDA Drug Approvals and Label Changes. Humatrope ISS indication (July 2003); Omnitrope approval (May 30, 2006); Increlex approval (August 30, 2005); Macrilen approval (December 20, 2017); Skytrofa approval (August 25, 2021); Sogroya adult (September 2020) and pediatric (April 28, 2023) approvals; Ngenla approval (June 27, 2023). Accessed via FDA.gov and Drugs@FDA database.

2. Endocrine Society. "Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline." J Clin Endocrinol Metab 2016; 101(11). Reaffirmed 2019.

3. Growth Hormone Research Society. "Consensus Guidelines for the Diagnosis and Treatment of Growth Hormone Deficiency in Childhood and Adolescence." Horm Res 2000; 2007 updates; 2016 workshop proceedings.

4. Bondy CA, Turner Syndrome Study Group. "Care of Girls and Women with Turner Syndrome: A Guideline of the Turner Syndrome Study Group." J Clin Endocrinol Metab 2007; 92(1). Updated recommendations 2017.

5. Leschek EW, et al. "Effect of Growth Hormone Treatment on Adult Height in Peripubertal Children with Idiopathic Short Stature: A Randomized, Double-Blind, Placebo-Controlled Trial." N Engl J Med 2004; 350(9):865–875.

6. Wit JM, et al. "Idiopathic Short Stature: Management and Growth Hormone Treatment." J Clin Endocrinol Metab 2012; 97(2):407–414.

7. Brod M, et al. (enliGHten trial investigators). "Once-Weekly Somapacitan vs Daily GH in Children with GH Deficiency: Results from a Randomized Phase 2 Trial." J Clin Endocrinol Metab 2020; 105(4).

8. Juul RV, et al. "Efficacy and Safety of Once-Weekly Somapacitan in Children Aged ≥2.5 Years with Growth Hormone Deficiency: A Multicenter, Randomized Trial." J Clin Endocrinol Metab 2022; 107(7).

9. Thornton PS, et al. "Once-Weekly Somatrogon vs Daily Somatropin in Children with Growth Hormone Deficiency: A Phase 3 Study." J Clin Endocrinol Metab 2021; 106(11).

10. Package Inserts. Norditropin (Novo Nordisk), Genotropin (Pfizer), Humatrope (Lilly), Omnitrope (Sandoz), Skytrofa (Ascendis), Sogroya (Novo Nordisk), Ngenla (Pfizer), Increlex (Ipsen), Macrilen (Novo Nordisk). Available at DailyMed.nlm.nih.gov.